A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
An integrated multidisciplinary center, unique in Belgium and internationally recognized, the Jules Bordet Institute is a hospital entirely dedicated to patients suffering from cancerous diseases.
Brussels, Belgium Clinical Trial Location
Institut Jules Bordet
Boulevard de Waterloo 121, 1000